Clinical trial
Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
NCT05902429 is registered in ClinicalTrials.gov with Pontificia Universidade Católica do Rio Grande do Sul as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
- Lead sponsor
- Pontificia Universidade Católica do Rio Grande do Sul
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- April 28, 2021
- Completion date
- August 31, 2024
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.